# Rentosertib AI-designed drug aging research

> Live situation record from CLSTR: https://clstr.news/situations/rentosertib-ai-designed-drug-aging-research
> Updated: 2026-09-09T20:57:44.000Z. Sources: 24. Developments: 2.

Insilico Medicine has developed an AI-designed drug candidate, rentosertib, which has shown potential in reducing biological aging markers during clinical trials. Originally intended to treat idiopathic pulmonary fibrosis (IPF), the drug targets the TNIK kinase.

In a Phase IIa clinical trial involving 42 patients, researchers used six independent proteomic aging clocks to analyze serum data. The models consistently indicated a reduction in predicted biological age among treated patients compared to a placebo group, with some models estimating a reduction of between 3 and 6 years. The most significant signals were observed around the fourth week of treatment. The study also noted dose-dependent improvements in Forced Vital Capacity (FVC), a measure of lung function. Specifically, patients in the 60mg once-daily dosage group saw a mean improvement of 98.4 milliliters, while the placebo group experienced a 20.3 milliliter decline.

Insilico Medicine utilized artificial intelligence for a dual purpose: identifying the TNIK enzyme as a target linked to both fibrosis and aging, and optimizing the drug molecule itself. While the results are promising for therapies addressing both specific diseases and the broader aging process, researchers cautioned that the study was small and that these measurements do not yet prove the drug can extend human lifespan or permanently reverse the aging process. Rentosertib has progressed to Phase III clinical trials.

## Claims

- In a Phase IIa clinical trial, six different proteomic aging clocks detected reductions in predicted biological age in patients treated with rentosertib. (corroborated by 5 sources)
- Insilico Medicine developed the experimental drug rentosertib using AI to identify the TNIK enzyme target and design the molecule. (corroborated by 4 sources)
- The rentosertib treatment was initially engineered to treat idiopathic pulmonary fibrosis (IPF). (corroborated by 4 sources)
- The proteomic aging clock analysis was conducted on 42 participants from a Phase IIa trial. (corroborated by 4 sources)
- Patients in the 60mg once-daily arm recorded a mean improvement in forced vital capacity of 98.4 milliliters compared to a 20.3 milliliter decline in the placebo group. (corroborated by 2 sources)
- The observed shift in biological age varied by model, ranging from approximately three to four years to nearly six years. (single source)

## Timeline

### 2026-09-09: Rentosertib, an AI-designed drug, shows potential to reduce biological aging

An AI-designed drug, rentosertib, has shown potential to reduce biological aging markers in patients with idiopathic pulmonary fibrosis during a Phase IIa clinical trial.

11 sources. https://clstr.news/cluster/insilico-medicines-ai-designed-drug-shows-potential-to-reduce-biological-aging

### 2026-09-07: Rentosertib AI-designed drug shows potential to reverse biological aging

An AI-designed drug, rentosertib, showed potential to reverse biological aging markers in a Phase IIa clinical trial for idiopathic pulmonary fibrosis, according to a study in Nature Biotechnology.

14 sources. https://clstr.news/cluster/insilico-medicine-advances-ai-designed-drug-rentosertib-to-phase-iii-trials

---
Cite as: Rentosertib AI-designed drug aging research. CLSTR, https://clstr.news/situations/rentosertib-ai-designed-drug-aging-research